Andrea P Sewell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea P Sewell has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Vaillant
Replicor Inc. Montréal, Canada
1 shared publication - David I. Bernstein
Cincinnati Children's Hospital Medical Center, University of Cincinnati , Cincinnati, Ohio
1 shared publication - Fernando J Bravo
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati Ohio, USA
1 shared publication - James E. Cummins
Southern Research Institute, 431 Aviation Way, Frederick, Maryland, 21701, USA
1 shared publication - Jean-Marc Juteau
REPLICor Inc 500 Blvd Cartier West, Suite 135, Laval, Quebec, H7V 5B7, Canada
1 shared publication - Louis Flamand
Université Laval
1 shared publication
Latest Publications
- Open Access
- 2 December 2009
- Published by Springer Nature in Virology Journal
- Vol. 6 (1) , 214
Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection
Phosphorothioated oligonucleotides (PS-ONs) have a sequence-independent, broad spectrum antiviral activity as amphipathic polymers (APs) and exhibit potent in vitro antiviral activity against a broad spectrum of herpesviruses: HSV-1, HSV-2, HCMV, VZV, EBV, and HHV-6A/B, and in vivo activity in a murine microbiocide model of genital HSV-2 infection. The activity of these agents against animal cytomegalovirus (CMV) infections in vitro and in vivo was therefore investigated.
- 2 December 2009
- Published by Springer Nature in Virology Journal
- Vol. 6 (1) , 214
Open AccessAmphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection
Phosphorothioated oligonucleotides (PS-ONs) have a sequence-independent, broad spectrum antiviral activity as amphipathic polymers (APs) and exhibit potent in vitro antiviral activity against a broad spectrum of herpesviruses: HSV-1, HSV-2, HCMV, VZV, EBV, and HHV-6A/B, and in vivo activity in a murine microbiocide model of genital HSV-2 infection. The activity of these agents against animal cytomegalovirus (CMV) infections in vitro and in vivo was therefore investigated.